APAC Natural Killer (Nk) Cell Therapeutics Market - Industry Trends And Forecast To 2029
- Published Date: 2022-12-24
- Report ID: 143410
- Pages: 225
-
Format:
Short Description
Asia-Pacific Natural Killer (NK) Cell Therapeutics Market, By Therapeutics (NK Cell Therapies, NK Cell Directed Antibodies), Approaches (Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), Bispecific Antibodies), Application (Cancer, Acute Infectious Diseases, Gastrointestinal Diseases, Others), End User (Research & Academic Institutes, Hospitals, Specialty Clinics), Distribution Channel (Hospital Pharmacies, Direct Tender, Others), Country (Japan, China, Australia, South Korea, India, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, rest of Asia-Pacific) Industry Trends and Forecast to 2029
Market Definition:
Natural killer (NK) cells are the large granular lymphocytes which have the ability to quickly respond to a pathological challenge. Natural killer cells are the important component of innate immune system and play an important role in generating immune response against the malignancies and infectious diseases caused by viral pathogens. Natural killer (NK) cells have been recognized to induce direct killing of targeted cells involving cancer cells. These have the ability to recognize the multitude of infected cells without being dependent on a single antigen expressing cells.
NK cells secrete cytokines and chemokines which recruit other immune cells such as T cells and B cells which enhances the immune response against the tumor cells. As Natural killer (NK) cells do not express T cell receptors, they induce low risk of graft-versus-host disease.
The effectiveness of NK cells therapies can be also be enhanced by genetically modified the NK cells so as to obtain highly specific and persistent cell lines. NK cell therapies can also be used with mono-clonal antibodies and T-cell therapies which again enhances its anti-tumor activity.
Increase in usage of natural killer cells for the treatment of cancer and infectious disease is a key factor responsible for market growth. Along with this rise in patients population with chronic disease and rise in the awareness about immunotherapies boosting the market growth.
Market Segmentation:
Natural killer (NK) cell therapeutics market is categorized into four notable segments which are based on therapeutics, approaches, application, end user, and distribution channel.
On the basis of therapeutics, the natural killer (NK) cell therapeutics market is segmented into NK cell therapies and NK cell directed antibodies
On the basis of approaches, the natural killer (NK) cell therapeutics market is segmented into antibody-dependent cell-mediated cytotoxicity (ADCC) and bispecific antibodies.
On the basis of application, the natural killer (NK) cell therapeutics market is segmented into cancer, acute infectious diseases, gastrointestinal diseases and others. Cancer is further sub-segmented into solid tumors, hematologic malignancies and others. Hematologic malignancies are further sub-segmented into multiple myeloma, acute myeloid leukemia (AML), lymphoma and others.
On the basis of end user, the natural killer (NK) cell therapeutics market is segmented into hospitals, specialty clinics, and research & academic institutes
On the basis of distribution channel, the natural killer (NK) cell therapeutics market is segmented into hospital pharmacies, direct tender, others.
Market Players
The key market players for natural killer (NK) cell therapeutics market are listed below:
Merck KGaA
Bristol-Myers Squibb Company
Glycostem
Kiadis Pharma
Cytovia Therapeutics
Nkarta, Inc.
Nektar
ImmunityBio, Inc.
Brink Biologics, Inc.
Biohaven Pharmaceuticals
Fate Therapeutics
EMERcell
Phio Pharmaceuticals
PersonGen BioTherapeutics
Innate Pharma, Inc.
INmuneBIO
Gamida Cell
Acepodia Inc.
Affimed GmbH
Multimmune GmbH
iCell Gene Therapeutics
Takeda Pharmaceutical Company Limited
Regeneron Pharmaceuticals Inc.
TABLE OF CONTENTS
1 INTRODUCTION 30
1.1 OBJECTIVES OF THE STUDY 30
1.2 MARKET DEFINITION 30
1.3 OVERVIEW OF ASIA PACIFIC NATURAL KILLER (NK) CELL THERAPEUTICS MARKET 30
1.4 LIMITATIONS 32
1.5 MARKETS COVERED 33
2 MARKET SEGMENTATION 35
2.1 MARKETS COVERED 35
2.2 GEOGRAPHICAL SCOPE 36
2.3 YEARS CONSIDERED FOR THE STUDY 37
2.4 CURRENCY AND PRICING 37
2.5 DBMR TRIPOD DATA VALIDATION MODEL 38
2.6 MULTIVARIATE MODELLING 41
2.7 THERAPEUTICS LIFELINE CURVE 41
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 42
2.9 DBMR MARKET POSITION GRID 43
2.10 SECONDARY SOURCES 45
2.11 ASSUMPTIONS 45
3 EXECUTIVE SUMMARY 46
3.1 EPIDEMIOLOGY 52
3.2 PESTEL ANALYSIS 53
3.3 PORTERS FIVE FORCES MODEL 54
3.4 INDUSTRIAL INSIGHTS: 55
3.5 PIPELINE ANALYSIS 57
4 ASIA PACIFIC NATURAL KILLER (NK) CELL THERAPEUTICS MARKET: REGULATIONS 58
5 MARKET OVERVIEW 60
5.1 DRIVERS 62
5.1.1 INCREASE IN USAGE OF NATURAL KILLER (NK) CELLS FOR THE TREATMENT OF CANCER AND INFECTIOUS DISEASES 62
5.1.2 INCREASE IN PATIENT POPULATION WITH CHRONIC DISEASES 62
5.1.3 RISE IN AWARENESS ABOUT IMMUNOTHERAPIES 63
5.1.4 ADOPTION OF NATURAL KILLER (NK) CELL THERAPY IN EMERGING MARKETS 63
5.2 RESTRAINTS 64
5.2.1 LACK OF SPECIFICITY AND POOR IN-VIVO SURVIVAL OF THE CELLS 64
5.2.2 ADVERSE SIDE EFFECTS OF THERAPIES 64
5.2.3 HIGH COST ASSOCIATED WITH THE THERAPIES 65
5.3 OPPORTUNITIES 66
5.3.1 ADVANCEMENT IN NATURAL KILLER (NK) CELL THERAPIES 66
5.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS 66
5.3.3 RISE IN EXPENDITURE IN HEALTHCARE SECTOR 67
5.4 CHALLENGES 67
5.4.1 LONG APPROVAL TIME FOR IMMUNOTHERAPIES 67
5.4.2 LACK OF SPECIFIC TREATMENT BY NATURAL KILLER (NK) CELLS 68
5.4.3 AVAILABILITY OF ALTERNATIVES FOR TUMOR TREATMENT 68
6 ASIA PACIFIC NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS 70
6.1 OVERVIEW 71
6.2 NK CELL THERAPIES 74
6.3 NK CELL DIRECTED ANTIBODIES 74
7 ASIA PACIFIC NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES 76
7.1 OVERVIEW 77
7.2 ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC) 80
7.3 BISPECIFIC ANTIBODIES 81
8 ASIA PACIFIC NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION 82
8.1 OVERVIEW 83
8.2 CANCER 86
8.2.1 SOLID TUMORS 87
8.2.2 HEMATOLOGIC MALIGNANCIES 87
8.2.2.1 MULTIPLE MYELOMA 88
8.2.2.2 ACUTE MYELOID LEUKEMIA (AML) 88
8.2.2.3 LYMPHOMA 88
8.2.2.4 OTHERS 88
8.2.3 OTHERS 88
8.3 IMMUNOPROLIFERATIVE DISORDERS 88
8.4 ACUTE INFECTIOUS DISEASES 89
8.5 GASTROINTESTINAL DISEASES 89
8.6 OTHERS 90
9 ASIA PACIFIC NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER 92
9.1 OVERVIEW 93
9.2 HOSPITALS 96
9.3 SPECIALTY CLINICS 96
9.4 RESEARCH & ACADEMIC INSTITUTES 97
10 ASIA PACIFIC NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL 99
10.1 OVERVIEW 100
10.2 HOSPITAL PHARMACIES 103
10.3 DIRECT TENDER 103
10.4 OTHERS 104
11 ASIA PACIFIC NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION 105
11.1 ASIA-PACIFIC 106
11.1.1 JAPAN 113
11.1.2 CHINA 115
11.1.3 AUSTRALIA 117
11.1.4 SOUTH KOREA 119
11.1.5 INDIA 121
11.1.6 SINGAPORE 123
11.1.7 MALAYSIA 125
11.1.8 THAILAND 127
11.1.9 INDONESIA 129
11.1.10 PHILIPPINES 131
11.1.11 VIETNAM 133
11.1.12 REST OF ASIA-PACIFIC 135
12 ASIA PACIFIC NATURAL KILLER (NK) CELLS THERAPEUTICS MARKET, COMPANY LANDSCAPE 136
12.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 136
13 SWOT ANALYSIS 137
14 COMPANY PROFILE 138
14.1 MERCK KGAA 138
14.1.1 COMPANY SNAPSHOT 138
14.1.2 RECENT FINANCIALS 138
14.1.3 PRODUCT PORTFOLIO 139
14.1.4 RECENT DEVELOPMENTS 139
14.2 BRISTOL-MYERS SQUIBB COMPANY 141
14.2.1 COMPANY SNAPSHOT 141
14.2.2 RECENT FINANCIALS 141
14.2.3 PRODUCT PORTFOLIO 142
14.2.4 RECENT DEVELOPMENTS 142
14.3 GLYCOSTEM 144
14.3.1 COMPANY SNAPSHOT 144
14.3.2 PRODUCT PORTFOLIO 144
14.3.3 RECENT DEVELOPMENTS 144
14.4 INNATE PHARMA, INC. 146
14.4.1 COMPANY SNAPSHOT 146
14.4.2 REVENUE ANALYSIS 146
14.4.3 PRODUCT PORTFOLIO 147
14.4.4 RECENT DEVELOPMENTS 147
14.5 REGENERON PHARMACEUTICALS INC. 149
14.5.1 COMPANY SNAPSHOT 149
14.5.2 RECENT FINANCIALS 149
14.5.3 PRODUCT PORTFOLIO 150
14.5.4 RECENT DEVELOPMENTS 150
14.6 TAKEDA PHARMACEUTICAL COMPANY LIMITED 151
14.6.1 COMPANY SNAPSHOT 151
14.6.2 RECENT FINANCIALS 151
14.6.3 PRODUCT PORTFOLIO 152
14.6.4 RECENT DEVELOPMENTS 152
14.7 INMUNEBIO 153
14.7.1 COMPANY SNAPSHOT 153
14.7.2 REVENUE ANALYSIS 153
14.7.3 PRODUCT PORTFOLIO 154
14.7.4 RECENT DEVELOPMENTS 154
14.8 KIADIS PHARMA 156
14.8.1 COMPANY SNAPSHOT 156
14.8.2 REVENUE ANALYSIS 156
14.8.3 PRODUCT PORTFOLIO 157
14.8.4 RECENT DEVELOPMENTS 157
14.9 ACEPODIA INC. 159
14.9.1 COMPANY SNAPSHOT 159
14.9.2 PRODUCT PORTFOLIO 159
14.9.3 RECENT DEVELOPMENTS 159
14.10 AFFIMED GMBH 161
14.10.1 COMPANY SNAPSHOT 161
14.10.2 RECENT FINANCIALS 161
14.10.3 PRODUCT PORTFOLIO 162
14.10.4 RECENT DEVELOPMENTS 162
14.11 BIOHAVEN PHARMACEUTICALS 164
14.11.1 COMPANY SNAPSHOT 164
14.11.2 REVENUE ANALYSIS 164
14.11.3 PRODUCT PORTFOLIO 165
14.11.4 RECENT DEVELOPMENTS 165
14.12 BRINK BIOLOGICS, INC. 166
14.12.1 COMPANY SNAPSHOT 166
14.12.2 PRODUCT PORTFOLIO 166
14.12.3 RECENT DEVELOPMENT 166
14.13 CYTOVIA THERAPEUTICS 167
14.13.1 COMPANY SNAPSHOT 167
14.13.2 PRODUCT PORTFOLIO 167
14.13.3 RECENT DEVELOPMENTS 167
14.14 EMERCELL 169
14.14.1 COMPANY SNAPSHOT 169
14.14.2 PRODUCT PORTFOLIO 169
14.14.3 RECENT DEVELOPMENTS 169
14.15 FATE THERAPEUTICS 170
14.15.1 COMPANY SNAPSHOT 170
14.15.2 REVENUE ANALYSIS 170
14.15.3 PRODUCT PORTFOLIO 171
14.15.4 RECENT DEVELOPMENTS 171
14.16 GAMIDA CELL 173
14.16.1 COMPANY SNAPSHOT 173
14.16.2 PRODUCT PORTFOLIO 173
14.16.3 RECENT DEVELOPMENTS 174
14.17 ICELL GENE THERAPEUTICS 175
14.17.1 COMPANY SNAPSHOT 175
14.17.2 PRODUCT PORTFOLIO 175
14.17.3 RECENT DEVELOPMENT 175
14.18 IMMUNITYBIO, INC. 176
14.18.1 COMPANY SNAPSHOT 176
14.18.2 REVENUE ANALYSIS 176
14.18.3 PRODUCT PORTFOLIO 177
14.18.4 RECENT DEVELOPMENTS 177
14.19 MULTIMMUNE GMBH 178
14.19.1 COMPANY SNAPSHOT 178
14.19.2 PRODUCT PORTFOLIO 178
14.19.3 RECENT DEVELOPMENTS 178
14.20 NEKTAR 179
14.20.1 COMPANY SNAPSHOT 179
14.20.2 REVENUE ANALYSIS 179
14.20.3 PRODUCT PORTFOLIO 180
14.20.4 RECENT DEVELOPMENTS 180
14.21 NKARTA, INC. 181
14.21.1 COMPANY SNAPSHOT 181
14.21.2 PRODUCT PORTFOLIO 181
14.21.3 RECENT DEVELOPMENTS 181
14.22 PERSONGEN BIOTHERAPEUTICS 183
14.22.1 COMPANY SNAPSHOT 183
14.22.2 PRODUCT PORTFOLIO 183
14.22.3 RECENT DEVELOPMENTS 183
14.23 PHIO PHARMACEUTICALS 185
14.23.1 COMPANY SNAPSHOT 185
14.23.2 PRODUCT PORTFOLIO 185
14.23.3 RECENT DEVELOPMENTS 185
15 QUESTIONNAIRE 187
16 RELATED REPORTS 191
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
